Sugi Predict

Sugi Predict / Compounds / SCHEMBL1354451

SCHEMBL1354451

SCHEMBL1354451

Cc1ccc(S(=O)(=O)n2c(I)cc3c(Br)ccnc32)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTGDR2 Q9Y5Y4 3/20 0.44
▸ L3MBTL1 Q9Y468 2/20 0.40
▸ ALDH3A1 P30838 2/20 0.39
▸ HTT P42858 2/20 0.39
▸ NOD1 Q9Y239 2/20 0.39
▸ POLB P06746 1/20 0.39
▸ COMT P21964 1/20 0.39
▸ PKM P14618 1/20 0.37
▸ CKS1B P61024 1/20 0.37
▸ SKP2 Q13309 1/20 0.37
▸ CA1 P00915 2/20 0.36
▸ CA2 P00918 2/20 0.36
▸ KDM4E B2RXH2 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ NPSR1 Q6W5P4 1/20 0.35
▸ GAA P10253 2/20 0.35
▸ MAPT P10636 1/20 0.35
▸ CXCL8 P10145 1/20 0.35
▸ NOD2 Q9HC29 1/20 0.35
▸ ABL1 P00519 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30668854 1.00 PTGDR2 (0.44) PTGDR2L3MBTL1ALDH3A1HTTNOD1
SCHEMBL30668847 0.88 PTGDR2 (0.46) PTGDR2L3MBTL1ALDH3A1HTTNOD1
SCHEMBL13548246 0.88 PTGDR2 (0.46) PTGDR2L3MBTL1ALDH3A1HTTNOD1
SCHEMBL1749156 0.87 PTGDR2 (0.46) PTGDR2L3MBTL1ALDH3A1HTTNOD1
SCHEMBL31634035 0.87 PTGDR2 (0.42) PTGDR2HTTNOD1PKMKDM4E
SCHEMBL4308888 0.87 PTGDR2 (0.42) PTGDR2HTTNOD1PKMKDM4E
SCHEMBL1749021 0.85 PTGDR2 (0.44) PTGDR2L3MBTL1ALDH3A1HTTNOD1
SCHEMBL13014031 0.85 PTGDR2 (0.44) PTGDR2L3MBTL1ALDH3A1HTTNOD1
SCHEMBL28694297 0.85 PTGDR2 (0.46) PTGDR2L3MBTL1ALDH3A1HTTNOD1
SCHEMBL1777233 0.82 PTGDR2 (0.42) PTGDR2L3MBTL1ALDH3A1HTTNOD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115976586-B Forward and reverse pulse electrolytic nickel-tungsten alloy solution, preparation method, electroplating method and nickel-tungsten alloy coating 昆山一鼎工业科技有限公司 2025-03-14 — — CN claimed
CN-115976586-A Positive and negative pulse electrolytic nickel-tungsten alloy solution, preparation method, electroplating method and nickel-tungsten alloy coating 昆山一鼎工业科技有限公司 2023-04-18 — — CN claimed
CN-115976586-B Forward and reverse pulse electrolytic nickel-tungsten alloy solution, preparation method, electroplating method and nickel-tungsten alloy coating 昆山一鼎工业科技有限公司 2025-03-14 — — CN disclosed
CN-117466884-A Heterocyclic compounds or salts thereof as ATR kinase inhibitors, pharmaceutical compositions containing same and uses thereof 德州大学系统董事会 2024-01-30 — — CN disclosed
EP-3651768-B1 HETEROCYCLIC INHIBITORS OF ATR KINASE UNIV TEXAS (US) 2023-12-20 — — EP disclosed
CN-111867590-B Heterocyclic inhibitors of ATR kinase 德州大学系统董事会 2023-11-17 — — CN disclosed
EP-3152210-B1 TANK-BINDING KINASE INHIBITOR COMPOUNDS GILEAD SCIENCES INC (US) 2023-07-05 — — EP disclosed
EP-3152210-B1 TANK-BINDING KINASE INHIBITOR COMPOUNDS GILEAD SCIENCES INC (US) 2023-07-05 — — EP disclosed
CN-115976586-A Positive and negative pulse electrolytic nickel-tungsten alloy solution, preparation method, electroplating method and nickel-tungsten alloy coating 昆山一鼎工业科技有限公司 2023-04-18 — — CN disclosed
US-11434233-B2 Heterocyclic inhibitors of ATR kinase BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2022-09-06 — — US disclosed
US-20210317134-A1 UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF RAPT THERAPEUTICS INC (US) 2021-10-14 — — US disclosed
US-20080176891-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2008-07-24 — — US disclosed
US-20080146606-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2008-06-19 — — US disclosed
US-20080146606-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2008-06-19 — — US disclosed
US-20080146606-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2008-06-19 — — US disclosed
WO-2008067119-A2 NOVEL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2008-06-05 — — WO disclosed
WO-2008049855-A2 7-AZAINDOLE DERIVATIVES AS C-MET KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2008-05-02 — — WO disclosed
WO-2008034860-A1 PYRROLO[2, 3-B]PYRIDIN-4-YL-BENZENESULFONAMIDE COMPOUNDS AS IKK2 INHIBITORS GLAXO GROUP LIMITED (GB) 2008-03-27 — — WO disclosed
WO-2008034860-A1 PYRROLO[2, 3-B]PYRIDIN-4-YL-BENZENESULFONAMIDE COMPOUNDS AS IKK2 INHIBITORS GLAXO GROUP LIMITED (GB) 2008-03-27 — — WO disclosed
WO-2003000690-A1 SYNTHESIS OF HETEROCYCLIC COMPOUNDS EMPLOYING MICROWAVE TECHNOLOGY AVENTIS PHARMACEUTICALS INC. (US) 2003-01-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176891-A1 NOVEL COMPOUNDS NFKBIA, IKBKG, IKBKE PTGDR2 1284/4885L3MBTL1 3702/4885ALDH3A1 4335/4885
US-11434233-B2 Heterocyclic inhibitors of ATR kinase ATR, CHEK1, CHEK2 PTGDR2 4094/4885L3MBTL1 1370/4885ALDH3A1 2695/4885
US-20210317134-A1 UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF USP7, SENP7, USP8 PTGDR2 4346/4885L3MBTL1 849/4885ALDH3A1 2215/4885
US-20080146606-A1 NOVEL COMPOUNDS NFKBIA, IKBKG, IKBKE PTGDR2 1284/4885L3MBTL1 3702/4885ALDH3A1 4335/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.